PRKACA and fibrolamellar hepatocellular carcinoma: For example, immunotherapeutic targeting of the hallmark DNAJB1-PRKACA fusion of fibrolamellar hepatocellular carcinoma appears particularly promising based on early findings of a patient with relapse-free survival (Bauer et al. 2022) coupled to related clinical trials underway.